A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib

被引：0
|
作者：
Jewitt, K.
Pilgrim, H. [1 ]
Ward, S. [1 ]
机构：
[1] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [41] Management of imatinib-resistant CML patients
    Linke, Rolf
    Dempke, Wolfram
    ONKOLOGIE, 2007, 30 (11): : 574 - 580
  • [42] Cost-utility analysis of evolocumab in patients with ASCVD in Italy
    Marcellusi, Andrea
    Bini, Chiara
    Rotundo, Maria Assunta
    Arcangeli, Emanuela
    Martinez, Laura
    Vilela, Francesc Sorio
    Mennini, Francesco Saverio
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 155 - 167
  • [43] Cost-utility analysis - Response
    Neumann, PJ
    Chapman, RH
    Stone, PW
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 626 - 626
  • [44] Cost-utility analysis of the rehabilitation of patients with musculoskeletal problems
    Jonsson D.
    Husberg M.
    Götherström U.
    International Advances in Economic Research, 2000, 6 (4) : 741 - 748
  • [45] Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase
    Warren, E
    Ward, S
    Gordois, A
    Scuffham, P
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1924 - 1933
  • [46] Cost-utility analysis and otolaryngology
    Hamilton, D.
    Hulme, C.
    Flood, L.
    Powell, S.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2014, 128 (02) : 112 - 118
  • [47] Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
    Gordois, A
    Scuffham, P
    Warren, E
    Ward, S
    BRITISH JOURNAL OF CANCER, 2003, 89 (04) : 634 - 640
  • [48] Early cost-utility analysis of genetically guided therapy for patients with drug-resistant epilepsy
    Gordon, Louisa G.
    Elliott, Thomas M.
    Bennett, Carmen
    Hollway, Georgina
    Waddell, Nicola
    Vadlamudi, Lata
    EPILEPSIA, 2022, 63 (12) : 3111 - 3121
  • [49] Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
    Pierri, Ivana
    Bergamaschi, Micaela
    Cagnetta, Antonia
    Ghiso, Anna
    Gobbi, Marco
    CLINICAL MANAGEMENT ISSUES, 2010, 4 : 23 - 26
  • [50] Compassionate use of nilotinib (AMN107) in Mexican patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib
    Ayala, Manuel
    Hurtado, Rafael
    Nacho, Kevin
    Tapia, Norma
    Alvarado, Martha
    Aguayo, Alvaro
    Cleto, Sergio
    Lugo, Yolanda
    Reyes, Gustavo
    Vargas, Pablo
    Herrera, Angel
    Meillon, Luis Antonio
    BLOOD, 2007, 110 (11) : 216B - 216B
12345